Relationship between Diabetes Mellitus and Cardiovascular Events in Hypertensive Patients Receiving Olmesartan-based Treatment (OMEGA Study Subanalysis)

DOI Web Site

Bibliographic Information

Other Title
  • オルメサルタン服用高血圧患者での糖尿病と脳・心血管系イベントの関係（OMEGA studyサブ解析）
  • 診断・治療(食事・運動・薬物) オルメサルタン服用高血圧患者での糖尿病と脳・心血管系イベントの関係(OMEGA studyサブ解析)
  • シンダン ・ チリョウ(ショクジ ・ ウンドウ ・ ヤクブツ) オルメサルタン フクヨウ コウケツアツ カンジャ デ ノ トウニョウビョウ ト ノウ ・ シンケッカンケイ イベント ノ カンケイ(OMEGA study サブ カイセキ)

Search this article

Description

We studied the relationships between the occurrence of cardiovascular events (CVD) and the presence/absence of diabetes mellitus, blood pressure and the HbA1c levels in 13,052 patients with no history of cardiovascular disease among those included in the full analysis set of the OMEGA study, a large-scale prospective observational study investigating the relationships between the occurrence of CVD and blood pressure and/or other risk factors in hypertensive Japanese patients receiving antihypertensive therapy based on the angiotensin II receptor blocker (ARB) olmesartan. During the 36-month study period, the incidence of CVD (per 1,000 subject-years) was 9.83 in the diabetic group (3,155 patients) and 4.23 in the nondiabetic group (9,897 patients). For the prevention of CVD, our results suggest that it is advisable to control the blood pressure to <140/90 mmHg in hypertensive patients with no history of cardiovascular disease and further control the HbA1c level to <7.0 % with a blood pressure of <130/80 mmHg in those with diabetes mellitus.

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top